We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , a global leader in musculoskeletal healthcare, recently launched PrimaGen Advanced Allograft. The product, which falls under its spine segment, has been designed to be used as an allogeneic bone graft substitute containing viable donor cells. Such cells are used for the repair, replacement, reconstruction or supplementation of a recipient's tissue in case of musculoskeletal defects. These damages may be a result of surgeries or traumatic bone injuries.
In the past six months, Zimmer Biomet beat the Zacks categorized Medical Product industry with respect to share price movement. However, the trend took a hit after the company reported a disappointing third quarter of 2016. The company’s trimmed full-year 2016 outlook also raises concern. The only saving grace for Zimmer Biomet is the 23.9% improvement in its Spine and CMF segment.
The stock lost 10.5% over the past six months compared to the broader industry’s decline of 2.9%. This apart, estimate revision trend for full-year 2016 remains dismal with 14 estimates moving south over the last 60 days. Earnings estimates have moved down by 5 cents over this period to $7.92 per share. However, we expect the introduction of PrimaGen Advanced Allograft to boost its share price.
PrimaGen Advanced Allograft has been designed to provide all the essential components for bone growth and healing: osteoconductivity, osteoinductivity and osteogenicity.The allograft also provides a trabecular structure for optimal handling and delivery characteristics.
Management claims that PrimaGen Advanced Allograft (human tissue transplanted from a donor to a patient) helps overcome the limitations of other bone graft substitutes and acts as a real alternative to autograft (transferred from one part of a patient's body to another). The new delivery system is easy to use, offering the same bone healing elements as autograft without the risks associated with donor site morbidity or harvest site complications.
As per a MarketsandMarkets report, the global spine implants market is expected to reach a worth of $17.27 billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021.
Meanwhile, management is constantly trying to develop its spine portfolio to cash in on the opportunities. Reportedly, in the third quarter, Zimmer Biomet’s spine offerings such as Mobi-C Cervical Disc prosthesis and Vitality Spinal Fixation System showed a considerable improvement in performance. The company considers itself to be well positioned in the spine business, courtesy of the acquisition of French spine device maker LDR Holding. We believe that the buyouts and new spine offerings will fortify Zimmer Biomet’s position in the market.
Zacks Rank & Stocks to Consider
Zimmer Biomet carries a Zacks Rank #4 (Sell). Better-ranked medical stocks are NxStage Medical Inc. , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy) while Bovie Medical carries a Zacks Rank #2. You can seethe complete list of today’s Zacks #1 Rank stocks here.
NxStage Medical surged 30.2% over the last one year compared with the S&P 500’s 11.2% over the same period. The company has a four-quarter average positive earnings surprise of 46.3%.
Baxter International rallied 20.8% over the last one year, much higher than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 27%.
Bovie Medical recorded a 113.2% gain in the past one year, way better than the S&P 500. The company has a trailing four-quarter positive average earnings surprise of 28.7%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zimmer Biomet (ZBH) Launches PrimaGen Advanced Allograft
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) , a global leader in musculoskeletal healthcare, recently launched PrimaGen Advanced Allograft. The product, which falls under its spine segment, has been designed to be used as an allogeneic bone graft substitute containing viable donor cells. Such cells are used for the repair, replacement, reconstruction or supplementation of a recipient's tissue in case of musculoskeletal defects. These damages may be a result of surgeries or traumatic bone injuries.
In the past six months, Zimmer Biomet beat the Zacks categorized Medical Product industry with respect to share price movement. However, the trend took a hit after the company reported a disappointing third quarter of 2016. The company’s trimmed full-year 2016 outlook also raises concern. The only saving grace for Zimmer Biomet is the 23.9% improvement in its Spine and CMF segment.
The stock lost 10.5% over the past six months compared to the broader industry’s decline of 2.9%. This apart, estimate revision trend for full-year 2016 remains dismal with 14 estimates moving south over the last 60 days. Earnings estimates have moved down by 5 cents over this period to $7.92 per share. However, we expect the introduction of PrimaGen Advanced Allograft to boost its share price.
PrimaGen Advanced Allograft has been designed to provide all the essential components for bone growth and healing: osteoconductivity, osteoinductivity and osteogenicity.The allograft also provides a trabecular structure for optimal handling and delivery characteristics.
ZIMMER BIOMET Price
ZIMMER BIOMET Price | ZIMMER BIOMET Quote
Management claims that PrimaGen Advanced Allograft (human tissue transplanted from a donor to a patient) helps overcome the limitations of other bone graft substitutes and acts as a real alternative to autograft (transferred from one part of a patient's body to another). The new delivery system is easy to use, offering the same bone healing elements as autograft without the risks associated with donor site morbidity or harvest site complications.
As per a MarketsandMarkets report, the global spine implants market is expected to reach a worth of $17.27 billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021.
Meanwhile, management is constantly trying to develop its spine portfolio to cash in on the opportunities. Reportedly, in the third quarter, Zimmer Biomet’s spine offerings such as Mobi-C Cervical Disc prosthesis and Vitality Spinal Fixation System showed a considerable improvement in performance. The company considers itself to be well positioned in the spine business, courtesy of the acquisition of French spine device maker LDR Holding. We believe that the buyouts and new spine offerings will fortify Zimmer Biomet’s position in the market.
Zacks Rank & Stocks to Consider
Zimmer Biomet carries a Zacks Rank #4 (Sell). Better-ranked medical stocks are NxStage Medical Inc. , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy) while Bovie Medical carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
NxStage Medical surged 30.2% over the last one year compared with the S&P 500’s 11.2% over the same period. The company has a four-quarter average positive earnings surprise of 46.3%.
Baxter International rallied 20.8% over the last one year, much higher than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 27%.
Bovie Medical recorded a 113.2% gain in the past one year, way better than the S&P 500. The company has a trailing four-quarter positive average earnings surprise of 28.7%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>